PTCT
PTC Therapeutics, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 115 | +8 | 58.79M | $4.78B | +13 | −5 |
| Q1 2026 | 110 | -8 | 65.31M | $4.45B | +9 | −18 |
| Q4 2025 | 117 | 0 | 67.93M | $5.16B | +1 | — |
| Q3 2025 | 22 | +2 | 38.04M | $2.33B | +2 | — |
| Q2 2025 | 17 | 0 | 34.63M | $1.69B | +1 | −1 |
| Q1 2025 | 14 | +2 | 16.93M | $862.87M | +2 | — |
| Q4 2024 | 12 | 0 | 14.84M | $670.12M | — | — |
| Q3 2024 | 11 | -2 | 14.00M | $519.42M | — | −2 |
| Q2 2024 | 13 | — | 14.28M | $436.54M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 8.21M | — | $251.02M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Wellington Management ✦ | 8.21M | — | $251.02M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Wellington Management ✦ | 8.21M | — | $251.02M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Wellington Management ✦ | 8.21M | — | $251.02M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Wellington Management ✦ | 8.21M | — | $251.02M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Wellington Management ✦ | 8.21M | — | $251.02M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | Wellington Management ✦ | 8.21M | — | $251.02M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | Geode Capital Management ✦ (passive) | 1.79M | — | $54.68M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Geode Capital Management ✦ (passive) | 1.79M | — | $54.68M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | D. E. Shaw & Co. ✦ | 1.36M | — | $41.52M | 0.1% | n/c | 1 | SEC ↗ |
| 11 | D. E. Shaw & Co. ✦ | 1.36M | — | $41.52M | 0.1% | n/c | 1 | SEC ↗ |
| 12 | D. E. Shaw & Co. ✦ | 1.36M | — | $41.52M | 0.1% | n/c | 1 | SEC ↗ |
| 13 | Renaissance Technologies ✦ | 818.10K | — | $25.02M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | T. Rowe Price ✦ | 606.68K | — | $18.55M | 0.0% | n/c | 1 | SEC ↗ |
| 15 | T. Rowe Price ✦ | 606.68K | — | $18.55M | 0.0% | n/c | 1 | SEC ↗ |
| 16 | Two Sigma Investments ✦ | 318.17K | — | $9.73M | 0.0% | n/c | 1 | SEC ↗ |
| 17 | Millennium Management ✦ | 317.58K | — | $9.71M | 0.0% | n/c | 1 | SEC ↗ |
| 18 | Adage Capital Partners ✦ | 300.00K | — | $9.17M | 0.0% | n/c | 1 | SEC ↗ |
| 19 | Citadel Advisors ✦ | 270.08K | — | $8.26M | 0.0% | n/c | 1 | SEC ↗ |
| 20 | Citadel Advisors ✦ | 270.08K | — | $8.26M | 0.0% | n/c | 1 | SEC ↗ |
| 21 | Marshall Wace ✦ | 179.68K | — | $5.49M | 0.0% | n/c | 1 | SEC ↗ |
| 22 | Marshall Wace ✦ | 179.68K | — | $5.49M | 0.0% | n/c | 1 | SEC ↗ |
| 23 | AQR Capital Management ✦ | 68.91K | — | $2.11M | 0.0% | n/c | 1 | SEC ↗ |
| 24 | AQR Capital Management ✦ | 68.91K | — | $2.11M | 0.0% | n/c | 1 | SEC ↗ |
| 25 | AQR Capital Management ✦ | 68.91K | — | $2.11M | 0.0% | n/c | 1 | SEC ↗ |
| 26 | Point72 Asset Management ✦ | 26.70K | — | $816,486 | 0.0% | n/c | 1 | SEC ↗ |
| 27 | Norges Bank ✦ (passive) | 15.10K | — | $461,758 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 4.16M shares, $5.53M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 2.39K sh · $171,793
Director · 691 sh · $50,388
Director · 9.42K sh · $666,677
Director · 7.17K sh · $527,846
Director · 5.33K sh · $388,708
Officer · 969 sh · $70,640
Officer · 1.84K sh · $133,487
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology